Kanilad (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. This stabilizes hyperexcitable neurons, limits repetitive firing, and thereby reduces the spread of epileptic activity without significantly affecting normal neuronal signaling.

The appropriate dose of Kanilad is determined by the prescribing healthcare professional based on the individual’s clinical condition, age, renal and hepatic function, and response to therapy. Patients should follow the dosage instructions provided by their prescriber.

Safety data for lacosamide in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Kanilad. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Kanilad (lacosamide) belongs to the sodium channel blocker class, offering a distinct mechanism that enhances slow inactivation of sodium channels. Compared with other agents such as carbamazepine or levetiracetam, lacosamide may have a different side‑effect profile and drug‑interaction potential, making it a useful alternative for patients who need additional seizure control.

Kanilad should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Kanilad is administered orally, typically as a tablet taken with or without food. The exact dosing schedule and whether it is taken once or twice daily are determined by the prescriber based on the patient’s therapeutic needs.

Serious risks include the potential for suicidal thoughts or behavior, severe skin reactions such as Stevens‑Johnson syndrome, cardiac conduction abnormalities like PR‑interval prolongation, and rare cases of respiratory depression, especially when combined with other central nervous system depressants.

Kanilad is contraindicated in patients with known hypersensitivity to lacosamide or any of its excipients, and it should be used with caution in individuals with significant cardiac conduction disorders, severe renal or hepatic impairment, or those taking medications that may cause dangerous interactions.